Abstract
Background To determinate the association relationship of breast cancer bone metastasis and cancer characteristics and molecular subtype. Furthermore, to evaluate the impact of molecular subtype on prevalence and prognosis of bone metastasis from the breast cancer base on a large population real-word program, the Surveillance, Epidemiology, and End Results (SEER) database. Methods We collected and analyzed the data obtained from SEER, which showed molecular subtype information for each patient. The prevalence and outcome of bone metastasis in breast cancer were estimated as per the different molecular subtypes. Results Occurrence of bone metastasis in conformity with four different molecular subtypes in all 42684 breast cancer patients was 6.2, 9.4, 7.9, and 6.4%, respectively. The most unfavorable subtype was the triple-negative breast cancer (TNBC), followed by the luminal A, luminal B, and HER2 subtypes (hazard ratio [HR] of luminal A compared with TNBC, 0.533, 95% confidence interval, 0.444–0.641; HR of luminal B, 0.482, 95% CI 0.419–0.555; HR of HER2 subtype, 0.542, 95% CI 0.484–0.608). Brain metastasis impacts overall survival (OS) (p < 0.001) fundamentally, and visceral metastases also significantly decreased OS (p < 0.001). Conclusion Bone metastasis patients present a more favorable oncological survival consequence than other metastases, and the TNBC subtype with bone metastasis showed the poorest tumor outcome compared with the other three molecular subtypes.
Highlights
To determinate the association relationship of breast cancer bone metastasis and cancer characteristics and molecular subtype
Bone Metastasis Rates Differ from Molecular Subtypes
In our study of cancer patients from 2011 to 2015 (N = 42684), luminal B breast cancer displayed the highest occurrence of bone metastasis (9.4%, 422/4502), and even in elderly patients with luminal B molecular subtype, the rate of bone metastasis was over 10%
Summary
To determinate the association relationship of breast cancer bone metastasis and cancer characteristics and molecular subtype. To evaluate the impact of molecular subtype on prevalence and prognosis of bone metastasis from the breast cancer base on a large population real-word program, the Surveillance, Epidemiology, and End Results (SEER) database. The prevalence and outcome of bone metastasis in breast cancer were estimated as per the different molecular subtypes. The bone has been the most common site of distant metastasis and results in unfavorable outcomes [3], including some amount of complications like bone fracture, pain, and hypercalcemia, which can hardly be cured [4]. The blooming and implementation of hormone and targeted treatment for the breast cancer subtype have promoted greatly the oncological outcomes even for end-stage patients [5, 6]. Predicting prognosis precisely of bone metastasis has become gradually urgent in choosing the most suitable therapy strategy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
